

David Z Cherney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11090894/publications.pdf>

Version: 2024-02-01

41
papers

1,379
citations

361413
20
h-index

345221
36
g-index

41
all docs

41
docs citations

41
times ranked

1939
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
2	A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812210812.	1.1	7
3	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. <i>Acta Diabetologica</i> , 2021, 58, 81-91.	2.5	24
4	Increased risk for microvascular complications among women with gestational diabetes in the third trimester The Microalbuminuria and Retinopathy in Gestational Diabetes (MARIGOLD) Study. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109068.	2.8	3
5	SGLT2â€inhibition reverts urinary peptide changes associated with severe COVIDâ€19: An inâ€silico proofâ€ofâ€principle of proteomicsâ€based drug repurposing. <i>Proteomics</i> , 2021, 21, e2100160.	2.2	3
6	Evaluation of novel glomerular filtration rate estimation equations in adolescents and young adults with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 36, 108081.	2.3	5
7	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107707.	2.3	22
8	Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 444-446.	4.5	5
9	Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812093570.	1.1	9
10	Use of sodiumâ€glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. <i>Cmaj</i> , 2020, 192, E351-E360.	2.0	53
11	Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 285-288.	4.5	23
12	Renal physiology of glucose handling and therapeutic implications. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i3-i12.	0.7	46
13	Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2020, 42, 467-477.	0.9	3
14	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107397.	2.3	8
15	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2511-2524.	2.8	54
16	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <i>Cmaj</i> , 2019, 191, E1128-E1135.	2.0	17
17	Renal SGLT mRNA expression in human health and disease: a study in two cohorts. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F1224-F1230.	2.7	18
18	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 2290-2297.	8.6	15

#	ARTICLE	IF	CITATIONS
19	Mineralocorticoid Antagonism and Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2019, 19, 4.	4.2	30
20	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1716-1723.	8.6	10
21	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€™Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	8.6	39
22	Sodium transport in diabetes: two sides to the coin. <i>Nature Reviews Nephrology</i> , 2019, 15, 125-126.	9.6	5
23	Effects of the SGLTâ€™ inhibitor dapagliflozin on glomerular and tubular injury markers. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1988-1993.	4.4	180
24	The Physiological Rationale for Incorporating Pulsatility in Continuous-Flow Left Ventricular Assist Devices. <i>Cardiology in Review</i> , 2018, 26, 294-301.	1.4	10
25	Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2018, 18, 22.	4.2	33
26	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. <i>Diabetes Care</i> , 2018, 41, 88-95.	8.6	17
27	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018, 41, 2560-2569.	8.6	239
28	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 660-664.	2.3	22
29	Social Determinants of Health Are Associated with Markers of Renal Injury in Adolescents with Type 1 Diabetes. <i>Journal of Pediatrics</i> , 2018, 198, 247-253.e1.	1.8	14
30	Neurohormone levels remain elevated in continuous flow left ventricular assist device recipients. <i>Journal of Cardiac Surgery</i> , 2018, 33, 403-411.	0.7	6
31	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>PLoS ONE</i> , 2018, 13, e0196647.	2.5	13
32	Assessment of urinary microparticles in normotensive patients with type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 581-584.	6.3	65
33	New therapy, new challenges: The effects of long-term continuous flow left ventricular assist device on inflammation. <i>International Journal of Cardiology</i> , 2016, 215, 424-430.	1.7	26
34	Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies. <i>Current Diabetes Reports</i> , 2016, 16, 11.	4.2	28
35	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. <i>Diabetes Care</i> , 2016, 39, e67-e68.	8.6	19
36	Renal Function Is Associated With Peak Exercise Capacity in Adolescents With Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 126-131.	8.6	22

#	ARTICLE	IF	CITATIONS
37	Longitudinal Assessment of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices. Canadian Journal of Cardiology, 2015, 31, 348-356.	1.7	34
38	Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrology Dialysis Transplantation, 2015, 30, 1706-1711.	0.7	88
39	Fat Mass Is Associated With Cystatin C and Estimated Glomerular Filtration Rate in Adolescents With Type 1 Diabetes. , 2015, 25, 454-455.		0
40	Insulin Sensitivity Is an Important Determinant of Renal Health in Adolescents With Type 2 Diabetes. Diabetes Care, 2014, 37, 3033-3039.	8.6	41
41	A Physiological Analysis of Hyponatremia: Implications for Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2001, 21, 1-9.	2.3	26